STOCK TITAN
  1. Home
  2. Sec-filings
  3. DNTH
  4. [EFFECT] Dianthus Therapeutics, Inc. /DE/ SEC Filing

[EFFECT] Dianthus Therapeutics, Inc. /DE/ SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: January 30, 2026 4:00 P.M.
Form: S-3
CIK: 0001690585
Company Name: Dianthus Therapeutics, Inc. /DE/
File Number: 333-293014

Source: View Original Filing on SEC EDGAR

Dianthus Therapeutics Inc

NASDAQ:DNTH

View DNTH Stock Overview →

DNTH Rankings

#1488 Ranked by Market Cap
N/A Ranked by Dividends

DNTH Latest News

Mar 12, 2026
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Mar 10, 2026
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
Mar 9, 2026
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
Mar 9, 2026
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results
Mar 9, 2026
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

DNTH Latest SEC Filings

Apr 1, 2026
[Form 4] Dianthus Therapeutics, Inc. /DE/ Insider Trading Activity
Apr 1, 2026
[Form 4] Dianthus Therapeutics, Inc. /DE/ Insider Trading Activity
Mar 31, 2026
[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing
Mar 31, 2026
[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing
Mar 26, 2026
[Form 4] Dianthus Therapeutics, Inc. /DE/ Insider Trading Activity

DNTH Stock Data

4.55B
48.95M
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK